New Report Keeps You up to Date on Companies and Developments in Apoptosis in Oncology.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48618) has announced the addition of Apoptosis in Oncology: Drug Pipeline Update 2007 to their offering. Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells. There are today over 190 apoptopic drugs in active development for the treatment of more than 40 different cancer indications. The field of apoptopic drug development in oncology is represented by more than 128 principal investigators plus their collaborators from more than 15 different countries. Apoptosis in Oncology: Drug Pipeline Update provides extensive research and development information with global coverage, vital for any serious player in the field. Read more below how Apoptosis in Oncology: Drug Pipeline Update is organized: Investigators Includes more than 128 investigators Drug name & Synonyms Lists commercial, generic and code names for drugs. In all more than 300 names Developmental stage Contains more than 190 apoptopic drugs in active development or more than 466 clinical projects for the treatment of cancer: * 28 projects in Phase III * 200 projects in Phase II * 140 projects in Phase I * 90 projects in Preclinical Cancer Indications Apoptopic drugs in development for over 40 cancer indications, with the five most targeted indications listed below: * Breast cancer * Leukemia * Lung cancer * Lymphoma * Prostate cancer Etc Target A 120 different targets are presented. Examples: * B-cell CLL/lymphoma 2 * BCL2-like 1 * breakpoint The location in a program used to temporarily halt the program for testing and debugging. Lines of code in a source program are marked for breakpoints. When those instructions are about to be executed, the program stops, allowing the programmer to examine the status of the program cluster region * carcinoembryonic antigen-related cell adhesion molecule Cell Adhesion Molecules (CAMs) are proteins located on the cell surface involved with the binding with other cells or with the extracellular matrix (ECM) in the process called cell adhesion. 5 * caspases * CD4 molecule * CD40 antigen (TNF TNF abbr. tumor necrosis factor TNF, n an abbreviation for tumor necrosis f receptor superfamily superfamily /su·per·fam·i·ly/ (soo´per-fam?i-le) 1. a taxonomic category between an order and a family. 2. member 5) * cyclin-dependent kinases * cytochrome P450, family 1, subfamily subfamily /sub·fam·i·ly/ (sub´fam-i-le) a taxonomic division between a family and a tribe. sub·fam·i·ly n. A taxonomic category ranking between a family and a genus. A, polypeptide 1 * eukaryotic translation elongation factor 1 alpha 1 * heat shock 90kDa protein 1, alpha * insulin-like growth factor 1 receptor The Insulin-like Growth Factor 1 (IGF-1) Receptor is a transmembrane receptor that is activated by IGF-1 and by the related growth factor IGF-II. It belongs to the large class of tyrosine kinase receptors. * interleukin 1 receptor-associated kinase 1 * Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse) * mitogen-activated protein kinase kinase Mitogen-activated protein kinase kinase (sic) is a kinase enzyme which phosphorylates mitogen-activated protein kinase. It is also known as MAP2K. It is classified as EC 2.7.12.2. 1 * apoptosis-inducing factor, mitochondrion-associated, 1 * protein kinase C Protein kinase C ('PKC', EC 2.7.11.13) is a family of protein kinases consisting of ~10 isozymes.[1] They are divided into three subfamilies: conventional (or classical), novel, and atypical based on their second messenger requirements. , beta 1 * superoxide dismutase 2, mitochondrial mitochondrial pertaining to mitochondria. mitochondrial RNAs a unique set of tRNAs, mRNAs, rRNAs, transcribed from mitochondrial DNA by a mitochondrial-specific RNA polymerase, that account for about 4% of the total cell RNA that * telomerase RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic component * Tumor Necrosis Factor tumor necrosis factor n. Abbr. TNF A protein that is produced in the presence of an endotoxin, especially by monocytes and macrophages, is able to attack and destroy tumor cells, and exacerbates chronic inflammatory diseases. (TNF) receptor superfamily, member 10b * tumor protein p53 (Li-Fraumeni syndrome) * Description Progress analysis and review of drug development. * A typical drug profile reports on: * Drug Name & Synonyms * Investigator(s) * Indication(s) * Developmental Stage(s) * Mechanism(s) * Target(s) * Clinical Development * Developmental History * Scientific Data * Patents * In/Out-licensing * Collaborations * Analysts Comments How May Drug Pipeline Update Be of Use? * Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intelligence operations * Excellent starting point for world wide benchmarking * Compare portfolio and therapy focus with your peers * Speed up pro-active in-/outlicensing strategy work * Fast and easy way of tracking drugs using search engines; just one click and you may search World Wide Web and PubMed for any drug with all its synonyms. For more information visit http://www.researchandmarkets.com/reports/c48618 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion